Valuation: Gilead Sciences, Inc.

Market Cap 187B 164B 155B 141B 265B 17,937B 266B 1,856B 719B 9,164B 703B 687B 29,451B P/E 2026 *
-45.6x
P/E 2027 * 18.8x
Enterprise Value 204B 179B 169B 154B 288B 19,542B 290B 2,022B 783B 9,984B 766B 749B 32,086B EV / Sales 2026 *
6.64x
EV / Sales 2027 * 6.01x
Free-Float
99.88%
Yield 2026 *
2.18%
Yield 2027 * 2.22%
09-25 HEALTH ROUNDS-Genetic discovery yields clues toward reversal of Alzheimer's brain damage RE
09-18 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
09-16 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
09-16 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
09-16 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
09-15 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
09-15 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
09-15 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
09-15 Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean RE
09-10 Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-10 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
09-09 Gilead Sciences, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09-08 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
1 day+0.83%
1 week+0.55%
Current month+3.14%
1 month+1.92%
3 months+18.02%
6 months+10.26%
Current year+22.97%
1 week 148.02
Extreme 148.02
154.2
1 month 142.94
Extreme 142.94
154.2
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/22/26 Exercice

Controller/Auditor

5,214 0.0004%
9/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
9/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+0.55%+34.64%+99.83% 187B
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
0.00%-10.14%-27.40%-61.08% 171B
+0.92%+3.65%+20.66%-11.51% 163B
Average +0.50%+1.03%+29.19%+42.47% 380.18B
Weighted average by Cap. +0.30%+1.42%+39.58%+64.79%

Financials

2026 *2027 *
Net sales 30.7B 26.94B 25.44B 23.19B 43.41B 2,943B 43.72B 304B 118B 1,503B 115B 113B 4,832B 32.68B 28.68B 27.09B 24.68B 46.21B 3,132B 46.54B 324B 126B 1,600B 123B 120B 5,143B
Net income -4.27B -3.75B -3.54B -3.23B -6.04B -410B -6.09B -42.39B -16.42B -209B -16.05B -15.7B -673B 10.28B 9.02B 8.52B 7.76B 14.53B 985B 14.63B 102B 39.47B 503B 38.58B 37.74B 1,617B
Net Debt 16.75B 14.69B 13.88B 12.65B 23.67B 1,605B 23.84B 166B 64.32B 820B 62.87B 61.51B 2,635B 9.12B 8.01B 7.56B 6.89B 12.9B 875B 12.99B 90.49B 35.05B 447B 34.26B 33.52B 1,436B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
150.93USD
Average target price
158.65USD
Spread / Average Target
+5.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock